NCT02652052

Hematopoietic Stem Cell Transplant Survivors Study

Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis.

Detailed description

Hematopoietic Stem Cell Transplant (HSCT) survivors are at an increased risk for premature aging. No one has evaluated the biologic markers of premature aging and senescence in HSCT survivors and their correlation with clinical outcomes, lifestyle, and nutrition. The investigators will evaluate age-related changes in HSCT survivors, with specified measures of premature aging, and employ therapeutic opportunities based on targeting senescent cells by conducting the first in-human pilot study of senolytic drugs (in HSCT survivors utilizing a combination of senolytics).

Conditions

• Stem Cell Transplant

Interventions

Type	Name	Description
OTHER	Standard of Care - Observation Only	Control Arm - Observation only
DRUG	Group 2: Quercetin	Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
DRUG	Group 2: Dasatinib	Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days

Timeline

• Start date: 2016-03-01
• Primary completion: 2023-05-23
• Completion: 2023-05-23
• First posted: 2016-01-11
• Last updated: 2025-01-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study